Sentences with phrase «safety and efficacy against»

Clinical trials that specifically test ADAR1 - targeted therapeutics for their safety and efficacy against multiple myeloma are still necessary before this approach could become available to patients.

Not exact matches

But oliceridine's value proposition actually depends on how well it stacks up against morphine from both a safety and efficacy standpoint, which is the secondary endpoint in each trial.

Respondents in this year's survey pointed to five main causes of the field's less than favorable reputation: drug and product recalls such as the withdrawal of Avandia; safety issues such as the discovery of problems with raw material from China used in medical products; scandals, including evidence that pharmaceutical companies have failed to release data from trials whose results cast doubts on their drugs» safety and efficacy; lawsuits brought against companies that failed to warn patients of problems with their products; and ethical issues such as kickbacks for physicians promoting specific medications.

«Results described in this manuscript provide a comprehensive characterization of the efficacy of the PMO antisense platform against Marburg virus in nonhuman primates and its safety profile in humans,» Bavari said.

In particular, more work is needed to determine the safety of this therapy in advanced mouse models that can more accurately predict safety in humans, and its efficacy specifically against metastatic cancer, which is the leading cause of cancer - related deaths.

A new paper published in the Journal of Allergy and Clinical Immunology has reported on a multicentre trial to test the safety and clinical efficacy of a new vaccine against grass pollen allergy in patients with grass pollen — induced rhinitis and controlled asthma.

We should guard against raising expectations of miracle cures for thousands of patients in the near future however as the current trial will require extensive tests for efficacy and safety.

The same year, the FDA approved the start of the first human clinical trial of this vaccine that demonstrated its safety and efficacy at inducing an immune response against the virus.

Safety and efficacy concerns with currently used drugs accentuate the need for new chemotherapeutic options against severe malaria.

According to Lise Alschuler, author of the Definitive Guide To Cancer: An Integrative Approach to Prevention, Treatment, and Healing, studies on flax lignans demonstrate safety and efficacy in their use against breast cancer, «inhibiting the growth of human estrogen - dependent breast cancer cells in mice and strengthening the tumor - inhibitory effect of tamoxifen».

Introducing VANGUARD ® CIV H3N2 / H3N8, a bivalent canine flu vaccine with demonstrated safety and efficacy for protection against both highly contagious H3N2 and H3N8 strains of canine influenza virus (CIV).

After all, the best way to help protect horses against EIV is to vaccinate before exposure to this highly contagious respiratory disease.8 And that's why horse owners can depend on the FLUVAC INNOVATOR vaccine line, because it helps offer demonstrated protection against EIV and is backed by the Zoetis commitment to continuously monitor and evaluate the efficacy and safety of its producAnd that's why horse owners can depend on the FLUVAC INNOVATOR vaccine line, because it helps offer demonstrated protection against EIV and is backed by the Zoetis commitment to continuously monitor and evaluate the efficacy and safety of its producand is backed by the Zoetis commitment to continuously monitor and evaluate the efficacy and safety of its producand evaluate the efficacy and safety of its producand safety of its products.

Non-structural protein 1 (NS1) truncated (NS1 - 126, NS1 - 99 and NS1 - 73) or deleted (DNS1) H3N8 canine influenza viruses (CIVs) were tested for their safety, immunogenicity and protection efficacy as live - attenuated influenza vaccines (LAIVs) against wild - type (WT) H3N8 CIV.

For example, the Human Rights Tribunal of Ontario has dismissed claims of discrimination against the Ontario Drug Benefit Program on the basis that there was no Code - related reason for denying coverage, but rather a dispute over its efficacy and safety as a medical treatment (e.g. Kueber v. Ontario (Attorney General), 2014 HRTO 769).